Pfizer finally makes decision on whether or not it will split into two companies

The rumors have been swirling around Pfizer's future and whether or not it would decide to split its giant status into separate companies.

As of Monday morning, it looks like the company finally reached a decision.

SEE ALSO: Pfizer to buy Medivation in $14 billion deal

Pfizer will remain one company and not pursue a split into multiple smaller companies.

As a company that's now a combination of older, established medical lines and newer pharmaceutical pursuits, it only makes sense that the option of a split was up for discussion.

The decision comes based upon the fact that a split would be of no value to shareholders.

Pfizer CEO Ian Read told the Wall Street Journal:

"We believe that by operating two separate and autonomous units within Pfizer we are already accessing many of the potential benefits of a split—sharper focus, increased accountability, and a greater sense of urgency— while also retaining the operational strength, efficiency and financial flexibility of operating as a single company."

Earlier this year, Pfizer called off a $150M mega-merger with Allergan, a Dublin based global pharmaceutical company, after technicalities with Obamacare would have required the merged company to move to Ireland for cheaper taxes.

Pfizer has made major acquisitions in the past, including Warner-Lambert in 2000 in a nearly $90M.

As of May 2016, Pfizer was valued at $205.7B.

RELATED: 17 health products and services that cost less at Costco

More on AOL.com:
Baby Boomers are facing a whole new retirement 'crisis'
The percentage of Americans without health insurance just hit an all-time low
Insured woman gets $18K bill for using an in-network doctor

Advertisement